Talk:Ischemic cascade
From Wikipedia, the free encyclopedia
 |
This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess. |
| Start | This page has been rated as Start-Class on the quality assessment scale |
| Low | This article has been rated as Low-importance on the importance assessment scale |
[edit] I
I don't know about the ischemic cascade in other tissues like the heart, so i limited this page to brain. If you know about other tissues, maybe you could add that in here, but i think a better idea would be to make this page be "Ischemic cascade in the brain" and make another page about the cascade other tissues. because the process in neural tissue is so different from other tissues, eg with anoxic depolarization. --Delldot 21:51, 8 October 2005 (UTC)
-
- Pretty much the same thing happens in all aerobic tissues. I have changed the article to reflect this. BTW, good review. Pproctor 14:57, 5 September 2006 (UTC)
[edit] Numbering
Someone recently changed the bullet points to numbers. [1] I'd suggest changing it back, since the numbers might imply that the events are sequential; rather, many are concurrent or circular. Would anyone object to changing it back? delldot | talk 23:30, 11 February 2007 (UTC)
[edit] NXY-059
I removed this last part from the article
However, NXY-059, the disulfonate derivative of the radical-scavenging spintrap phenylbutylnitrone, has been reported to give neuroprotection in Phase III human trials.<ref name="lees">Kennedy R. Lees, Justin A. Zivin, Tim Ashwood, Antonio Davalos, Stephen M. Davis, Hans-Christoph Diener, James Grotta, Patrick Lyden, Ashfaq Shuaib, Hans-Göran Hårdemark, Warren W. Wasiewski, for the Stroke–Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. 2006. [http://content.nejm.org/cgi/content/short/354/6/588 NXY-059 for Acute Ischemic Stroke.] ''New England Journal of Medicine''. Volume 354, Pages 588-600. Retrieved on [[January 9]], [[2007]].</ref>
According to a more recent study, NXY-059 is not efficient.
...however, the repeat study,found no difference between treated and placebo control groups on the same outcome measure (Hill, 2007; Shuaib et al., 2007). AstraZeneca has subsequently withdrawn NXY-059 from further development. Ref: Savitz, S.I.; A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: A need for more rigorous testing of neuroprotective agents in animal models of stroke, Experimental Neurology 205 (2007) 20–25
Bobsodium (talk) 06:48, 17 March 2008 (UTC)
